Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have recently received a lot of national attention. Repurposing GLP-1R agonists to treat some central nervous disorders is promising, but comparatively understudied. At a September 2024 workshop, the National Academies Forum on Neuroscience and Nervous System Disorders reviewed the current knowledge and research gaps about the mechanisms of action of GLP-1R agonists in the brain, and the evidence of their clinical efficacy for eating disorders, neurodegenerative diseases, substance use disorders, and pain.
National Academies of Sciences, Engineering, and Medicine. 2025. Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
Sign in to access your saved publications, downloads, and email
preferences.
Former MyNAP users: You'll need to reset your password on your first
login to MyAcademies. Click "Forgot password" below to receive a reset
link via email. Having trouble?
Visit our FAQ page
to contact support.
Members of the National Academy of Sciences, National Academy of
Engineering, or National Academy of Medicine should log in through their
respective Academy portals.
Register
Register
Thank You
Thank You
Thank you for creating a MyAcademies account!
Enjoy free access to thousands of National Academies' publications, a
10% discount off every purchase, and build your personal library.
Forgot Password
Forgot Password
Enter the email address for your MyAcademies (formerly MyNAP) account to
receive password reset instructions.
Reset Requested
Reset Requested
We sent password reset instructions to
your email
. Follow the link in that email to create a new password. Didn't receive
it? Check your spam folder or
contact us
for assistance.
We sent a verification link to your email. Please check your inbox (and
spam folder) and follow the link to verify your email address. If you
did not receive the email, you can request a new verification link below